Clinical trialNCT04830878WithdrawnPhase 1Interventional

Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients

SponsorStanford UniversityEnrollment0Proliferative Vitreoretinopathy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Rhegmatogenous retinal detachment (RRD) is a sight-threatening condition. Children with RRD usually present late with clinical features of longstanding RRD, specifically a serious condition named: proliferative vitreoretinopathy (PVR). Therefore, children with RRD often have poorer outcomes. The objective of this study is to investigate the efficacy and safety of methotrexate in the treatment and prevention of PVR. Methotrexate is a medication that has been used to treat inflammatory conditions in children and adults for a long time and it has been recently used to treat PVR in adults.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Ahmad Al-Moujahed, MD, PhD, MPH
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Darius Moshfeghi, MD
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Edward Wood, MD
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Hashem Ghoraba, MD
Stanford University
Principal Investigator
clinicaltrials.gov ↗
Quan Dong Nguyen, MD, MSc
Stanford University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Byers Eye Institute at Stanford University and Lucille Packard Children Hospital
Palo Alto, California, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Methotrexate →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2021
Primary completion: 30 Apr 2023
Completion: 30 Apr 2024
Last update posted: 20 Apr 2023
Registered enrollment: 0
Registry id: NCT04830878

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.